Dr. Jeffrey T. Chang is an Assistant Professor of Integrative Biology and Pharmacology in the School of Medicine and McWilliams School of Biomedical Informatics (by adjunct) in the University of Texas Health Science Center at Houston. He is interested in personalized medicine with respect to the understanding of the progression and treatment of cancer. His lab leverages a multidisciplinary approach to understanding genetic and non-genetic drivers of cancer and metastasis, specifically focusing on cholesterol metabolism, intertumor and intratumor heterogeneity, and regulators of the stem cell phenotype.
Research
Cell Signaling Programs in Cancer
Assistant Professor, Integrative Biology and Pharmacology - McGovern Medical School
Publications
- Ergin S, Lee HJ, Zhang Y, Huang LC, Chen X, Wei Q, Zheng JW, Chang JT, Cohen T, Sun J, and Xu H. CATTLE (CAncer Treatment Treasury with Linked Evidence) - An Integrated Knowledgebase for Personalized Oncology Research and Practice. Accepted, CPT: Pharmacometrics and Systems Pharmacology.
- Boyle G, Priest HD, Richter K, Traver D, Chang JT, Mockler TC, Kay SA, and Breton G. Comparative analysis of vertebrate diurnal/circadian transcriptomes. PLoS One, accepted.
- Chen X and Chang JT. Planning bioinformatics workflows using an expert system. Bioinformatics, accepted.
- Tsai WB, Long Y, Estecio M, Chang JT, Savaraj N, Feun LG, and Kuo MT. Cisplatin-induced Argininosuccinate
- Synthetase Downregulation Resulting in Synthetic Lethal to Arginine-Depleting Agent Is Mediated by Transcriptional Upregulation of HIF-1a and Downregulation of c-Myc and Independent of DNA Methylation. Oncotarget, accepted.
- Tang X, Wu J, Ding CK, Sjol J, Lu M, Lin CA, Keenan M, Lin CC, Wang CC, Wardell S, George D, McDonnell DP, Hsu DS, Chang JT, and Chi JT. Cell-type specific cystine addiction associated with distinct signaling amplification of programmed necrosis. Oncogene, accepted.
- Mansouri S, Singh S, Alamsahebpour A, Burrell K, Li M, Karabork M, Ekinci C, Solaroglu I, Chang J, Aldape K, and Zadeh G. DICER Governs Characteristics of Glioma Stem Cells and the Resulting Tumors in Xenograft Mouse Models of GBM. Oncotarget, 2016.
- Werden SJ*, Sphyris N*, Sarkar TR, Paranjape AN, LaBaff AM, Taube JH, Hollier BG, Ramirez-Peña EQ, Soundararajan R, Den Hollander P, Powell E, Echeverria G, Miura N, Chang JT, Piwnica-Worms H, Rosen JM, and Mani SA. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene, 2016.
- Tisza MJ, Fuentes JSR, Zhao W, Chen X, Levental I*, and Chang JT*. Motility and stem cell properties induced by the Epithelial-Mesenchymal Transition require destabilization of lipid rafts. Oncotarget, 2016.
* Co-Corresponding Authors - Chen CY, Chang JT, Ho YF, and Shyu AB. MiR-26 down-regulates TNF-?/NF-?B signaling and IL-6 expression by silencing HMGA1 and MALT1. NAR 44(8), 2016.
- Xu Y, Chang JT, Myers MG, Xu Y, and Tong Q. Euglycemia restoration by central leptin in type 1 diabetes requires STAT3 signaling but not fast-acting neurotransmitter release. Diabetes, 2016.
- Zhao W, Prijic W, Urban BC, Tisza MJ, Li L, Tan Z, Chen X, Mani SA, and Chang JT. Candidate anti-metastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Research 76(7):2037-49, 2016.
- Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, Davies MA, Wistuba II, and Kuo MT. Gas6/Axl is the sensor of Arginine-Auxotrophic Response in Targeted Chemotherapy with Arginine-Depleting Agents. Oncogene 35(13):1632-42, 2016.
- Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Dhillon J, Mahajan N, Mahajan K, Chang JT, Ittmann M, Maity SN, Logothetis C, Miura N, Tang DG, and Mani SA. Inhibition of FOXC2 restores epithelial phenotype and drug-sensitivity in prostate cancer cells with stem-like properties. Oncogene, 2016.